Close

Abzena appoints Matthew LeClair as SVP and Site Head of San Diego Operations

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Matthew LeClair as Senior Vice President (SVP) and Site Head of its San Diego Operations.

With more than 29 years’ experience in the biopharmaceutical industry, Matt has previously held roles at Takeda, including Site Head in Singapore and Site Head of the Milford, Massachusetts facility. Prior to joining Takeda, Matthew was at Stryker Biotech.

Matthew brings with him extensive experience of multiple technology transfers, developing site expansion plans, and ensuring start-up and licensure of manufacturing suites. He has also previously achieved manufacturing success through the deployment of several operational excellence initiatives.

Before entering the health care industry, he was in the United States Navy as an Aviation Electricians Mate 2nd Class. He received his Bachelor of Science in Business Administration at Colorado Technical University in Colorado Springs, Colorado.

About Abzena

Abzena is a leading partner research organization which offers discovery, design, development and cGMP manufacture of biologics, bioconjugates and complex or highly potent small molecules to the global biopharmaceutical industry. From its facilities in the UK and US the company provides its customers with concept to clinic solutions. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back